Previous reports showed associations between psoriasis and chronic diseases. Little is known about the association between osteoporosis and psoriasis. The goal of the study was to assess the association between psoriasis and osteoporosis in a population-based case-control study, utilizing the database of a large health-care provider organization in Israel, Clalit Health Services. Patients (aged 51-90 years) diagnosed with psoriasis were compared with a sample of age-and sex-matched enrollees without psoriasis regarding the prevalence of osteoporosis. Data on health-related lifestyles and other comorbidities were collected. The study included 7,936 psoriasis cases and 14,835 controls. The prevalence of osteoporosis was significantly greater in males with psoriasis compared with the control group (3.1 vs 1.7%, Po0.001, odds ratio (OR) ¼ 1.86, 95% confidence interval (CI): 1.44-2.39) and slightly greater in females with psoriasis (22.3 vs 20.2%, P ¼ 0.008, OR ¼ 1.13, 95% CI: 1.03-1.25).
INTRODUCTION
Psoriasis is a chronic inflammatory disease of the skin that is prevalent in the general population (2-4%) (Langley et al., 2005; Schö n and Henning-Boehricke, 2005) . Recent evidence shows that psoriasis is associated with complex chronic comorbidity (Naldi et al., 2005; Gelfand et al., 2006; Mallbris et al., 2006; Neimann et al., 2006; Sterry et al., 2007; Wakkee et al., 2007) . Psoriasis is associated with markers of systemic inflammation and a high frequency of cardiovascular events, diabetes, and dyslipidemia (Naldi et al., 2005; Gelfand et al., 2006; Mallbris et al., 2006; Neimann et al., 2006; Sterry et al., 2007; Wakkee et al., 2007) .
Osteoporosis is defined as a reduction in bone mass and disruption of the microarchitecture of bone, resulting in decreased bone strength leading to an increased risk of fractures (Poole and Compston, 2006; Lindsay and Cosman, 2008) . The World Health Organization defines osteoporosis as a bone mineral density (BMD) that falls 2.5 standard deviations below the mean for young healthy adults of the same sex, whereas T scores between À2.5 and À1 standard deviations are defined as osteopenia (WHO, 1994) . Common locations for osteoporotic fractures are the spine, hip, wrist, humerus, and pelvis. Hip fractures result in the loss of independence for at least one-third of people with osteoporosis, and vertebral fractures cause height loss, chronic pain, and difficulty with normal daily activities (Poole and Compston, 2006) .
Osteoporosis occurs more frequently in women than in men, particularly postmenopausal women, and is more common with increasing age. Age-related bone loss starts in the fourth or fifth decade of life. In women, the loss of ovarian function at menopause (around age 50 years) results in rapid bone loss due to estrogen deficiency (Poole and Compston, 2006; Lindsay and Cosman, 2008) . Osteoporosis is an under-recognized problem in men, and it is untreated in the majority of men with fractures (Ebeling, 2008) . Bone mass in elderly men is also positively related to estrogen levels. Genetic factors have a strong influence on peak bone mass attained during the third decade of life, which is an important determinant of bone mass later in life. Nutritional factors, including calcium and vitamin D intake, hormonal status, and physical activity, also influence peak bone mass (Poole and Compston, 2006) . Vitamin D deficiency and secondary hyperparathyroidism are common in elderly people. Additional risk factors include cigarette smoking, alcohol consumption, and reduced physical activity, as well as chronic inflammatory diseases, malabsorption states, hypogonadism, endocrine disorders, severe liver disease, rheumatoid arthritis, ankylosing spondylitis, hematological malignancies, chronic obstructive pulmonary disease, sarcoidosis, amyloidosis, multiple sclerosis, and other rare diseases (Poole and Compston, 2006; Ebeling, 2008; Lindsay and Cosman, 2008) .
Recent advances in understanding the pathogenesis of osteoporosis shed light on the role of various cytokines, including IFN-g, IL-6, and tumor necrosis factor (TNF-a) in osteoporosis (Raisz, 2005; Duque and Troen, 2008; Lindsay and Cosman, 2008; Tilg et al., 2008) . The same cytokines appear to be active in the pathogenesis of psoriasis as well (Hofbauer et al., 2006; Kastelan et al., 2006) .
In previous studies, we have described the association between psoriasis and other diseases including diabetes (Shapiro et al., 2007) and chronic obstructive lung disease (Dreiher et al., 2008) . The purpose of this study was to assess the association between psoriasis and osteoporosis utilizing the large medical dataset of Clalit Health Services (CHS).
RESULTS
The study initially included 12,405 psoriasis cases and 24,096 age-and sex-matched controls aged 20-90 years. As the prevalence of osteoporosis was very low in those younger than 51 years (49/12,929 ¼ 0.4%), we focused on patients older than 51 years. The final sample included 7,936 cases and 14,835 controls. Despite matching, psoriasis cases were slightly older (mean age: 65.6 vs 65.2, P ¼ 0.003) and were more likely to be male (51.8 vs 48.7%, Po0.001). Psoriasis patients were more frequently diagnosed with other diseases and unhealthy lifestyles, some of which are associated with osteoporosis (Table 1) . Of 109 chronic diagnoses included in the database, 56 were significantly more prevalent among cases as compared with controls (Po0.05 in a univariate analysis). Overall, in addition to psoriasis, cases had 5.0 ± 3.3 chronic diagnoses, whereas controls had 3.7 ± 3.0 (Po0.001). Psoriasis patients were significantly more likely to be treated with acitretin. No difference in other medications, including anti-TNF-a, IFN-a, and azathioprine, was noted (Table 1) . None of these medications, including acitretin, was associated with osteoporosis (data not shown).
Overall, osteoporosis was diagnosed among 12.4% of cases, compared with 11.2% of controls (P ¼ 0.007; odds ratio (OR) ¼ 1.12, 95% confidence interval (CI): 1.03-1.22). As the mechanisms underlying osteoporosis are quite different in men and women, we analyzed the association between psoriasis and osteoporosis separately by sex.
Among males, the prevalence of osteoporosis was significantly higher among cases than among controls (3.1 vs 1.7%, Po0.001, respectively; OR ¼ 1.86, 95% CI: 1.44-2.39). We performed a stratified analysis in various subgroups (Tables 2 and 3 ). The prevalence increased with age in both cases and controls, but the strength of the association decreased with increasing age (Table 2) . Thus, a statistically significant effect modification by age was observed (P ¼ 0.006 for effect modification). Blindness was also found to be an effect modifier of the association (P ¼ 0.01 for effect modification). Analysis of the association between psoriasis and osteoporosis in males with and without known risk factors for osteoporosis is listed in Table 2 .
Among females, the prevalence of osteoporosis was much greater than in males, and only slightly greater among cases than among controls (22.3 vs 20.2%, respectively; P ¼ 0.008, OR ¼ 1.13, 95% CI: 1.03-1.25). The prevalence increased with age in both cases and controls. Only in women older than 80 years psoriasis was significantly associated with osteoporosis (Table 3) . A stratified analysis for additional risk factors appears in Table 3 .
A multivariate logistic regression model demonstrated that among males, psoriasis was associated with osteoporosis even after controlling for confounders, including age, the presence of inflammatory bowel disease, and the number of chronic diagnoses (OR ¼ 1.35, 95% CI: 1.04-1.75, P ¼ 0.024, Table 4 ). Among females, the weak association lost statistical significance in the multivariate model, after controlling for various confounders (OR ¼ 0.90, 95% CI: 0.80-1.00, P ¼ 0.049, Table 5 ). 
DISCUSSION
This study is a population-based case-control study, based on a large sample of patients with psoriasis and controls from the CHS database. Psoriasis was found to be associated with a greater prevalence of osteoporosis among males, an association that was somewhat attenuated after controlling for potential confounders. In contrast, the association between psoriasis and osteoporosis among females was rather weak, and lost statistical significance after controlling for confounders.
Our understanding of the pathogenesis of osteoporosis has improved recently. Bone remodeling is regulated by both systemic hormones (estrogens, androgens, vitamin D, and parathyroid hormone) and locally produced factors (transforming growth factor-b, parathyroid hormone-related peptide, ILs, and TNFs). Several factors, including IL-1, IL-6, IL-11, parathyroid hormone, thiazolidinediones, and TNF, are known to promote bone damage, whereas others (estrogens, calcitonin, transforming growth factor-b, platelet-derived growth factor, IL-17, and mechanical force) aid bone repair (Duque and Troen, 2008; Lindsay and Cosman, 2008) . Three members of the TNF and TNF receptor superfamily are involved. Hematopoietic cells bear the receptor activator of NF-kB (RANK). Osteoblasts produce RANK ligand (RANKL), which activates the differentiation of osteoclasts and maintains their function. Osteoblasts also produce and secrete osteoprotegerin, a decoy receptor that can block RANK--RANKL interactions. Stimulators of bone resorption increase RANKL expression in osteoblasts, and some also increase osteoprotegerin expression. Osteoclast activation may therefore be initiated by inflammatory cells, particularly T cells (Raisz, 2005; Tilg et al., 2008) TNF-a is the key proinflammatory cytokine that directly and indirectly promotes inflammation-associated osteoporosis. IL-1b enhances osteoclastogenesis in the presence of permissive levels of RANKL. IL-6 is a cytokine of the acute-phase response. Neutralizing anti-IL-6 antibodies inhibit osteoclast formation. IFN-g causes bone loss, in particular by enhancing T cell activation. IFN-g can also inhibit osteoclastogenesis when directly acting on developing osteoclasts (Tilg et al., 2008) .
These mechanisms suggest that osteoporosis could be considered an immunological disorder. Clinical observations reveal colocalization of regional inflammation, as well as coincidence of systemic osteoporosis with periods of systemic inflammation. Old age is characterized by an acceleration of diseases that are increasingly attributed to inflammation. Cytokines such as IL-6, TNF-a, and IL-1 are elevated during senescence and play direct roles in the pathogenesis of these diseases (De Martinis et al., 2006) . Some reports show direct correlation between serum osteoprotegerin, cytokine levels, and disease activity in several inflammatory disorders, including rheumatoid arthritis, primary biliary cirrhosis, and inflammatory bowel disease (Rodriguez-Bores et al., 2007) .
Several mechanisms for the apparent association between psoriasis and osteoporosis can be suggested. Psoriasis is a chronic inflammatory state (Langley et al., 2005) and chronic inflammation might be an important component in the pathogenesis of osteoporosis. Cytokines related to osteoporosis play a major role in psoriasis. T lymphocytes affect epidermal growth homeostasis by inducing increased keratinocyte proliferation and abnormal differentiation. Activation of T cells is a key step in psoriasis. Psoriasis is characterized by the Th-1 type cytokine pattern with the predominant secretion of IL-2, IL-6, IFN-g, and TNF-a. Some of these cytokines are produced by keratinocytes, rather than by T cells (Langley et al., 2005; Schö n and Henning-Boehricke, 2005; Kastelan et al., 2006) .
Most studies on the association between psoriasis and osteoporosis (Nymann et al., 1996; Millard et al., 2001; Borman et al., 2008) included few patients. Osteoporosis has been linked to palmoplantar pustular psoriasis (Nymann et al., 1996) , but not to chronic plaque psoriasis (Millard et al., 2001) , although patients with psoriatic arthritis had lower BMD. Hofbauer et al. (2006) evaluated BMD as well as cytokine levels related to bone remodeling in psoriatic arthritis. Osteopenia was found in 35% of women and 31% of men with psoriatic arthritis; osteoporosis was detected in one woman (1.8%) and six men (10.2%). Psoriatic arthritis patients had similar osteoprotegerin levels, but higher levels of TNF-related apoptosis-inducing ligand (Hofbauer et al., 2006) . In another study, no significant difference between psoriasis patients with and without arthritis was found, although both groups had BMD below that of age-matched controls. In the arthritis group, one patient (5%) had osteoporosis and nine (50%) had osteopenia (Borman et al., 2008) . In the group without arthritis, none had osteoporosis and eight (27.5%) had osteopenia. A study from Sweden (Osmancevic et al., 2008) reported a greater BMD at the hip among women with psoriasis treated with UVB than among controls; no differences in BMD values at the spine were noted. The greater BMD was attributed to a higher body weight and UVB therapy, which replenishes vitamin D in the skin of patients in this Scandinavian country, in which sun exposure in winter is minimal. This difference probably does not play a major role in this study, conducted in a sunny country like Israel. Some studies found BMD values similar to healthy controls among patients with psoriatic arthritis (Grisar et al., 2002) , whereas others reported lower BMD (Frediani et al., 2001; Millard et al., 2001) . It has been hypothesized that psoriasis is related to an increased risk of osteoporosis due to enhanced activity of IL-6 and TNF-a (Kastelan et al., 2006) . Additional explanations linking psoriasis with osteoporosis might include a lack of physical activity, smoking, and alcohol consumption, which are known risk factors for osteoporosis (Poole and Compston, 2006; Duque and Troen, 2008; Lindsay and Cosman, 2008) , and are common in patients with psoriasis (Naldi et al., 2005) . Topical corticosteroids are not considered to be sufficiently absorbed to the extent of increasing the risk of osteoporosis, although they have been shown to be associated with other metabolic disorders, such as diabetes mellitus.
It is of interest to note that the association between psoriasis and osteoporosis in this study was significant only among men. Similar to previous studies, osteoporosis was much more common in women. Osteoporosis among women www.jidonline.org 1645 J Dreiher et al.
is usually the result of estrogen deficiency, and menopause seems to be a stronger risk factor for osteoporosis than psoriasis. In contrast, osteoporosis in males is more commonly the result of a systemic disease, which in this case was found to be psoriasis. Alternatively, as women are more likely to be routinely referred to BMD scans, men diagnosed with osteoporosis are more likely to represent a chronically ill population. Similarly, the association between psoriasis and osteoporosis among males was not statistically significant above the age of 80 years, probably because in this subgroup, age is a stronger risk factor for osteoporosis than psoriasis.
This study has some potential limitations. Directionality of the association cannot be established with certainty. We had no data on the severity and duration of psoriasis or osteoporosis. Hormonal status was similarly unavailable. Data regarding physical activity were missing, as this information is rarely recorded in the computerized files. Blindness and depression are incomplete proxies for physical activity. Many of the chronic diagnoses were associated with psoriasis. This could be explained by clustering of chronic illnesses (that is, a patient with one chronic illness is more likely to be diagnosed with additional disease), or by the fact that diseases with common risk factors are likely to be associated with each other in a univariate analysis. Although a potential detection bias cannot be completely excluded, we had no reason to suspect that psoriasis patients are more commonly referred to BMD scans. To conclude, an association between psoriasis and osteoporosis was observed among males, but not among females. It would be interesting to further assess the association in patients with psoriatic arthritis. Further prospective studies are needed to substantiate our observation. Nevertheless, we suggest that psoriasis might be associated with an elevated risk for osteoporosis, at least among men, who should be advised to increase their level of physical activity and make sure their calcium and vitamin D intake is adequate. This study supported the claim that psoriasis patients should be observed for development of complex comorbidity.
It may be reasonable to suggest that patients with other chronic inflammatory illnesses should be evaluated for osteopenia and/or osteoporosis, as the inflammatory state, the medications used, and the related inactivity associated with the inflammatory disease places this population at risk for accelerated bone mineral loss.
MATERIALS AND METHODS
Data mining techniques were used for the current case-control study, utilizing the CHS database. CHS is the largest health provider organization in Israel, serving a population of approximately 3,800,000 enrollees. CHS maintains a comprehensive computerized database with continuous real-time input from pharmaceutical, medical, and administrative computerized operating systems, facilitating studies of associations between chronic disease states.
Cases were patients with at least one documented diagnosis of psoriasis in the medical records registered by a CHS physician. No data regarding specific treatments or confirmation of the diagnosis by a dermatologist were available. Controls were randomly selected from the list of CHS enrollees, excluding patients with a diagnosis of psoriasis and frequency matched to psoriasis patients on sex and age (within eight intervals of 5-10 years, pre-defined in the database, that is, 20-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85 years and older) . Patients in the age range of 20-90 years were initially included in this study, but as the prevalence of osteoporosis was very low in patients younger than 51 years, we focused on those over the age of 51 years. Data available from the database included age, sex, ethnicity, socioeconomic status, and chronic diagnoses including osteoporosis and diseases suspected or known as risk factors for osteoporosis (for example, current smoking, thyroid disorders, inflammatory bowel disease, chronic hepatitis, rheumatoid arthritis, and chronic obstructive pulmonary disease), states associated with decreased physical activity (depression and blindness), and obesity (a protective factor against osteoporosis), as well as a large variety of diagnoses (109 individual codes for chronic disease). The diagnoses of chronic diseases, including osteoporosis, were taken from the CHS chronic diseases registry, which is based on data withdrawn from hospital and primary care physicians' reports. The registry is validated by primary physician confirmation of registered diagnoses of chronic diseases on an on-going basis. The validity of diagnoses in the register was previously estimated and found to be high for important chronic diagnoses (Rennert and Peterburg, 2001) . Data regarding systemic medications for psoriasis were available as of 1998 and extracted from the central pharmaceutical database.
Person-time was not available, as the date of diagnoses is not reliably registered in the database. Data on disease severity were also missing. No data regarding hormonal status for women or physical activity were available. Psoriasis patients and controls were randomly selected from all CHS practices, without matching of controls to patients regarding the place of residence or practice.
The proportions of patients with osteoporosis were compared between patients with and without psoriasis by univariate analyses, using w 2 tests and t-tests for comparison of categorical and continuous parameters between the groups, respectively. 95% CIs for OR were calculated and rounded outward. Where the point estimate for the OR was 0, the 95% CI was calculated using the Cornfield method. Stratified analysis was performed to test for confounding and effect modification. Effect modification was identified when the P-value in Tarone's test of homogeneity was o0.05. Logistic regression models were used to measure the association between psoriasis and osteoporosis in a multivariate analysis. Variables introduced into the multivariate model were those with P-value o0.1 in the univariate analysis. Variables retained in the model were those with Po0.05 in the multivariate analysis, those that changed the OR for psoriasis and osteoporosis by 10% or more, or those that contributed significantly to the fit of the model. The analysis was performed separately for males and females. In the logistic regression models, Nagelkerke R 2 estimates are reported. Statistical analysis was performed using SPSS software (version 13) and Stata software (version 8).
The study was approved by the institutional review board of Soroka University Medical Center, and the Declaration of Helsinki Principles protocols were followed.
